Narrow search
Showing 1 - 10 of 720,100
Cover Image
A ban on "private label" generic pharmaceuticals : legal and economic context
Anis, Aslam H.; Harvard, Stephanie - In: International journal of the economics of business 22 (2015) 2, pp. 219-229
Persistent link: https://www.econbiz.de/10011405945
Cover Image
Market definition in the pharmaceutical industry : a case of drugs hopping antitrust markets?
Ornaghi, Carmine; Siotis, Georges; Castanheira, Micael - 2019
Persistent link: https://www.econbiz.de/10012197768
Cover Image
On the economics of labels : how their introduction affects the functioning of markets and the welfare of all participants
Bonroy, Olivier; Constantatos, Christos - In: American journal of agricultural economics 97 (2015) 1, pp. 239-259
Persistent link: https://www.econbiz.de/10011294215
Cover Image
Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market
Bokhari, Farasat A. S.; Yan, Weijie - 2020
pharmaceuticals to examine how incumbents respond to change in the threat of entry. In line with the entry deterrence motive …
Persistent link: https://www.econbiz.de/10012285099
Cover Image
An empirical model of drug detailing : dynamic competition and policy implications
Liu, Qiang; Gupta, Sachin; Venkataraman, Sriram; Liu, Hongju - In: Management science : journal of the Institute for … 62 (2016) 8, pp. 2321-2340
Persistent link: https://www.econbiz.de/10011539516
Cover Image
Reference pricing systems on the pharmaceutical market
Unsorg, Maximiliane - 2018
Constantly rising expenditures for pharmaceuticals require government intervention in firms' pricing decisions. To this … implementing the regulation. …
Persistent link: https://www.econbiz.de/10011976973
Cover Image
Heterogeneous merger impacts on competitive outcomes
Siebert, Ralph - 2017
differential merger outcomes are caused mostly by firms' technology or product market attributes. Furthermore, empirical merger …. We allow the merger responses to vary across firms, even after controlling for regressors, and apply a random …
Persistent link: https://www.econbiz.de/10011717038
Cover Image
Late-stage pharmaceutical R & D and pricing policies under two-stage regulation
Jobjornsson, Sebastian; Forster, Martin; Pertile, Paolo; … - 2015
Persistent link: https://www.econbiz.de/10011411614
Cover Image
Price caps versus reimbursement limits : pharmaceutical regulation under market integration through parallel trade
Birg, Laura - 2019 - Revised Version March 2019
manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South … via reimbursement limits. Parallel trade may relax regulation in the source country of parallel imports (South) and … intensify regulation in the destination country (North): In the source country, parallel trade may relax regulation both under a …
Persistent link: https://www.econbiz.de/10011986314
Cover Image
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation
Jobjörnsson, Sebastian; Forster, Martin; Pertile, Paolo; … - In: Journal of health economics 50 (2016), pp. 298-311
Persistent link: https://www.econbiz.de/10011589153